Original Article by Nqobile Dludla | Reuters | 20 July 2026
Aspen Semaglutide Canada gains Health Canada approval, but API supply problems could delay the generic’s commercial launch.
AI Image | Chat-GPT
Aspen Pharmacare has received Health Canada approval for Aspen-Semaglutide, its generic version of Novo Nordisk’s diabetes medicine Ozempic.
Aspen, Africa’s largest pharmaceutical manufacturer, announced that its Canadian subsidiary had secured the regulatory authorisation.
The medicine has been approved for the management of type 2 diabetes. The decision gives Aspen access to Canada’s expanding market for GLP-1 medicines.
Ambulance tariff negotiations could help private emergency service providers address low payments, cash-flow pressure and market contraction.
Read more...
Learn how Discovery Health aims for robust membership growth amid challenges posed by churn and an aging member pool.
Read more...
Medscheme Bonitas Court Bid withdrawal allows the CMS to resume its forensic probe into disputed Bonitas procurement processes.
Read more...